The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Updates with bezuclastinib in non-advanced and advanced systemic mastocytosis: SUMMIT & APEX trials
In this interview, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares updates from the pivotal SUMMIT and APEX trials (NCT05186753 and NCT04996875, respectively) investigating bezuclastinib in non-advanced and advanced systemic mastocytosis (SM). Both trials have demonstrated encouraging results, suggesting that bezuclastinib may provide a novel therapeutic option in patients with this disease. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
